A maker of kits and instruments that extract, purify, and analyze DNA, RNA, and proteins from biological samples, QIAGEN's "Sample to Insight" products are used by research labs, hospitals, and forensic scientists around the world. Founded in 1984 in Düsseldorf, Germany, as Diagen by three doctoral students and their professor, it was one of the first biotech spin-offs from a German university. The "Q" in its name comes from "Q-Smaragd," the special resin in its first plasmid-purification kits.
QIAGEN Q1 2026 net sales $492M, adjusted EPS $0.54, in line with outlook
Q1 2026 net sales rose 2% reported to $492M, but declined 1% at constant exchange rates (CER) vs. prior year.
Show detailsHide details
Adjusted diluted EPS was $0.54 (also $0.54 CER), in line with the outlook for at least $0.54 CER.
QuantiFERON sales fell 5% CER due to significantly lower immigration testing demand in the U.S. and Middle East.
Full-year 2026 outlook updated: net sales growth of about 1-2% CER (previously at least 5%) and adjusted diluted EPS of at least $2.43 CER (previously at least $2.50).
Free cash flow was $54M in Q1 2026, down from $96M in Q1 2025, reflecting higher investments and restructuring payments.
QIAGEN reports preliminary Q1 2026 net sales of $492M, updates FY2026 outlook
Preliminary Q1 2026 net sales were $492 million, up 2% reported and down 1% at constant exchange rates (CER) versus prior year.
Show detailsHide details
Adjusted diluted EPS for Q1 2026 expected to be $0.54 on a reported basis and $0.54 CER, in line with outlook.
QuantiFERON sales declined 5% CER due to significantly lower immigration testing demand in the U.S. and Middle East.
Full-year 2026 net sales growth outlook reduced to about 1-2% CER (previously at least 5% CER); adjusted EPS outlook lowered to at least $2.43 CER (previously at least $2.50 CER).
Q2 2026 net sales expected to decline about 2% CER from $534 million in Q2 2025; adjusted EPS expected at least $0.60 CER.
QIAGEN Q4 2025 net sales $540M, FY 2025 $2.09B, 2026 outlook at least 5% CER growth
Adjusted diluted EPS for Q4 2025 was $0.62 CER, above the outlook of about $0.60; FY 2025 adjusted diluted EPS was $2.40 CER, ahead of the outlook of about $2.38.
Show detailsHide details
Q4 2025 net sales rose 4% to $540 million, with 1% CER growth, exceeding the outlook for steady results.
Full-year 2025 net sales grew 6% to $2.09 billion, with 5% CER growth, at the high end of the outlook.
For 2026, QIAGEN expects net sales growth of at least 5% CER and adjusted diluted EPS of at least $2.50 CER.
Growth pillars delivered $1.49 billion CER in 2025 sales, up 8% CER, and are expected to contribute about $1.64 billion CER in 2026.
QIAGEN to complete ~$500M synthetic share repurchase on January 7, 2026
QIAGEN announced details for completing a synthetic share repurchase of up to approximately $500 million, with the last trading day of pre-split shares on January 7, 2026.
Show detailsHide details
The plan combines a direct capital repayment of $2.29 per pre-consolidation share with a reverse stock split consolidating every 20 shares into 19, reducing issued shares by about 10.9 million.
The capital return is expected to reduce issued shares by approximately 5% and enhance earnings per share.
QIAGEN will have returned at least $1 billion to shareholders by end-2028, well ahead of schedule, and is considering additional return measures.
The repayment will be made from existing cash reserves, with consolidated shares trading under current tickers (QIA, QGEN) starting January 8, 2026.